Zacks Research Increases Earnings Estimates for Alkermes

Alkermes plc (NASDAQ:ALKS - Free Report) - Analysts at Zacks Research raised their FY2025 earnings estimates for Alkermes in a note issued to investors on Tuesday, July 1st. Zacks Research analyst R. Department now forecasts that the company will earn $1.55 per share for the year, up from their prior forecast of $1.54. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' FY2026 earnings at $1.98 EPS, Q1 2027 earnings at $0.32 EPS, Q2 2027 earnings at $0.48 EPS and FY2027 earnings at $1.68 EPS.

ALKS has been the topic of a number of other reports. Royal Bank Of Canada lifted their price target on Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Needham & Company LLC began coverage on Alkermes in a research note on Wednesday, May 28th. They issued a "buy" rating and a $45.00 target price on the stock. UBS Group raised shares of Alkermes from a "neutral" rating to a "buy" rating and increased their price target for the company from $33.00 to $42.00 in a research report on Tuesday, June 17th. HC Wainwright restated a "neutral" rating on shares of Alkermes in a report on Friday, May 2nd. Finally, Wall Street Zen lowered shares of Alkermes from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $40.00.

Alkermes Stock Performance

NASDAQ:ALKS traded down $0.25 during trading hours on Thursday, reaching $28.75. The company's stock had a trading volume of 1,122,189 shares, compared to its average volume of 1,737,488. The stock has a 50 day moving average price of $30.12 and a two-hundred day moving average price of $30.90. The company has a market capitalization of $4.74 billion, a P/E ratio of 13.76, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.45.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a net margin of 23.30% and a return on equity of 27.52%. The business had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. During the same quarter in the prior year, the firm posted $0.43 EPS. The company's revenue for the quarter was down 12.6% compared to the same quarter last year.

Institutional Trading of Alkermes

Several large investors have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC acquired a new stake in shares of Alkermes during the fourth quarter worth about $940,000. Fisher Asset Management LLC raised its position in Alkermes by 27.1% during the 4th quarter. Fisher Asset Management LLC now owns 331,359 shares of the company's stock worth $9,530,000 after buying an additional 70,574 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Alkermes by 558.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company's stock valued at $85,000 after acquiring an additional 2,502 shares during the period. Cornerstone Investment Partners LLC purchased a new stake in shares of Alkermes in the 4th quarter valued at $203,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Alkermes in the fourth quarter worth $12,293,000. Hedge funds and other institutional investors own 95.21% of the company's stock.

Insider Activity at Alkermes

In related news, SVP Christian Todd Nichols sold 3,334 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the transaction, the senior vice president directly owned 86,208 shares of the company's stock, valued at $2,680,206.72. This represents a 3.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.40% of the company's stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.